Endometrial hyperplasia medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[Progesterone]] therapy is the preferred drug for the treatment of [[benign]] hyperplasia. The management of endometrial hyperplasia depends upon the desire for future childbearing.<ref name="pmid25797956">{{cite journal| author=Emons G, Beckmann MW, Schmidt D, Mallmann P, Uterus commission of the Gynecological Oncology Working Group (AGO)| title=New WHO Classification of Endometrial Hyperplasias. | journal=Geburtshilfe Frauenheilkd | year= 2015 | volume= 75 | issue= 2 | pages= 135-136 | pmid=25797956 | doi=10.1055/s-0034-1396256 | pmc=PMC4361167 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25797956 }} </ref> | [[Progesterone]] therapy is the preferred drug for the treatment of [[benign]] hyperplasia. The management of endometrial hyperplasia depends upon the desire for future childbearing.<ref name="pmid25797956">{{cite journal| author=Emons G, Beckmann MW, Schmidt D, Mallmann P, Uterus commission of the Gynecological Oncology Working Group (AGO)| title=New WHO Classification of Endometrial Hyperplasias. | journal=Geburtshilfe Frauenheilkd | year= 2015 | volume= 75 | issue= 2 | pages= 135-136 | pmid=25797956 | doi=10.1055/s-0034-1396256 | pmc=PMC4361167 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25797956 }} </ref><ref name="pmid15623473">{{cite journal| author=Baak JP, Mutter GL| title=EIN and WHO94. | journal=J Clin Pathol | year= 2005 | volume= 58 | issue= 1 | pages= 1-6 | pmid=15623473 | doi=10.1136/jcp.2004.021071 | pmc=PMC1770545 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15623473 }} </ref><ref name="pmid15623473">{{cite journal| author=Baak JP, Mutter GL| title=EIN and WHO94. | journal=J Clin Pathol | year= 2005 | volume= 58 | issue= 1 | pages= 1-6 | pmid=15623473 | doi=10.1136/jcp.2004.021071 | pmc=PMC1770545 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15623473 }} </ref> | ||
==Medical Therapy== | ==Medical Therapy== | ||
*Patients with endometrial hyperplasias without [[atypia]] are treated conservatively, whereas patients with atypical hyperplasia or endometrioid intraepithelial neoplasia are treated surgically.<ref name="pmid25797956">{{cite journal| author=Emons G, Beckmann MW, Schmidt D, Mallmann P, Uterus commission of the Gynecological Oncology Working Group (AGO)| title=New WHO Classification of Endometrial Hyperplasias. | journal=Geburtshilfe Frauenheilkd | year= 2015 | volume= 75 | issue= 2 | pages= 135-136 | pmid=25797956 | doi=10.1055/s-0034-1396256 | pmc=PMC4361167 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25797956 }} </ref> | *Patients with endometrial hyperplasias without [[atypia]] are treated conservatively through normalization of the menstrual cycles, whereas patients with atypical hyperplasia or endometrioid intraepithelial neoplasia are treated surgically.<ref name="pmid25797956">{{cite journal| author=Emons G, Beckmann MW, Schmidt D, Mallmann P, Uterus commission of the Gynecological Oncology Working Group (AGO)| title=New WHO Classification of Endometrial Hyperplasias. | journal=Geburtshilfe Frauenheilkd | year= 2015 | volume= 75 | issue= 2 | pages= 135-136 | pmid=25797956 | doi=10.1055/s-0034-1396256 | pmc=PMC4361167 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25797956 }} </ref><ref name="pmid15623473">{{cite journal| author=Baak JP, Mutter GL| title=EIN and WHO94. | journal=J Clin Pathol | year= 2005 | volume= 58 | issue= 1 | pages= 1-6 | pmid=15623473 | doi=10.1136/jcp.2004.021071 | pmc=PMC1770545 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15623473 }} </ref><ref name="pmid15623473">{{cite journal| author=Baak JP, Mutter GL| title=EIN and WHO94. | journal=J Clin Pathol | year= 2005 | volume= 58 | issue= 1 | pages= 1-6 | pmid=15623473 | doi=10.1136/jcp.2004.021071 | pmc=PMC1770545 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15623473 }} </ref> | ||
{{familytree/start |summary=Treatment of endometrial hyperplasia}} | {{familytree/start |summary=Treatment of endometrial hyperplasia}} | ||
Line 26: | Line 26: | ||
{{familytree |boxstyle=background: #DCDCDC; | | D01 | |D02 | | D03 | | D04 | |D01=<div style="width: 9em; padding:0.2em;">'''[[Weight loss]]''' </div> |D02=<div style="width: 9em; padding:0.2em;">'''[[Metformin]]''' </div> |D03=<div style="width: 9em; padding:0.2em;">'''[[Oral contraceptive pills]]''' </div> |D04=<div style="width: 9em; padding:0.2em;">'''[[Progestin]]s (cyclic/continuous)''' </div>}} | {{familytree |boxstyle=background: #DCDCDC; | | D01 | |D02 | | D03 | | D04 | |D01=<div style="width: 9em; padding:0.2em;">'''[[Weight loss]]''' </div> |D02=<div style="width: 9em; padding:0.2em;">'''[[Metformin]]''' </div> |D03=<div style="width: 9em; padding:0.2em;">'''[[Oral contraceptive pills]]''' </div> |D04=<div style="width: 9em; padding:0.2em;">'''[[Progestin]]s (cyclic/continuous)''' </div>}} | ||
{{familytree/end}} | {{familytree/end}} | ||
==References== | ==References== |
Revision as of 03:24, 24 March 2016
Endometrial hyperplasia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Endometrial hyperplasia medical therapy On the Web |
American Roentgen Ray Society Images of Endometrial hyperplasia medical therapy |
Risk calculators and risk factors for Endometrial hyperplasia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]
Overview
Progesterone therapy is the preferred drug for the treatment of benign hyperplasia. The management of endometrial hyperplasia depends upon the desire for future childbearing.[1][2][2]
Medical Therapy
- Patients with endometrial hyperplasias without atypia are treated conservatively through normalization of the menstrual cycles, whereas patients with atypical hyperplasia or endometrioid intraepithelial neoplasia are treated surgically.[1][2][2]
Treatment of endometrial hyperplasia | |||||||||||||||||||||||||||||||||||||||||||||
Hyperplasia without atypia
| Hyperplasia with atypia | ||||||||||||||||||||||||||||||||||||||||||||
Conservative
| Desire for pregnancy? | ||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||
Conservative
| |||||||||||||||||||||||||||||||||||||||||||||
Progestins (cyclic/continuous) | |||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ 1.0 1.1 Emons G, Beckmann MW, Schmidt D, Mallmann P, Uterus commission of the Gynecological Oncology Working Group (AGO) (2015). "New WHO Classification of Endometrial Hyperplasias". Geburtshilfe Frauenheilkd. 75 (2): 135–136. doi:10.1055/s-0034-1396256. PMC 4361167. PMID 25797956.
- ↑ 2.0 2.1 2.2 2.3 Baak JP, Mutter GL (2005). "EIN and WHO94". J Clin Pathol. 58 (1): 1–6. doi:10.1136/jcp.2004.021071. PMC 1770545. PMID 15623473.